Sign In

Wednesday, October 24, 2018 - 12:00pm to 1:00pm
Add to Calendar

Content Contributor

Hepatitis B SIG

Presenter(s)

Kosh Agarwal, MBBS
Norah Terrault, MD, MPH, FAASLD

Moderator(s)

Marc Ghany, MD, FAASLD

Details

This webinar will focus on reviewing the highlights of the revised AASLD Clinical Practice Guidelines for HBV infection in the first talk. The second presentation will address a key area of controversy, namely the role of antiviral therapy in patients during the immunotolerant phase of chronic HBV infection.

Presenter Bio

Kosh Agarwal, MBBS

Dr. Kosh Agarwal is a Consultant Hepatologist and Transplant Physician at the Institute of Liver Studies, King’s College Hospital. Dr Agarwal is the Lead for the Kings Viral Hepatitis Service, the largest treatment centre for viral hepatitis in the UK. In 1991 Dr Agarwal graduated from Newcastle University and his postgraduate training was undertaken in Newcastle with the majority of his clinical and research training at the Regional Liver and Transplant Unit.

Prior to his appointment at King’s, Dr Agarwal was a consultant and honorary senior lecturer at the Regional Liver and Transplant Unit in Newcastle. He also spent a year at the Division of Liver Diseases, Mount Sinai, New York, USA. Dr Agarwal is an investigator for several ongoing studies evaluating the safety and efficacy of various antiviral treatment regimens for chronic Hepatitis B and C. He is a member of the EASL, AASLD, BASL, & ILTS.

Norah Terrault, MD, MPH, FAASLD

Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California, San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation. She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines.

She has served as Associate Editor for HEPATOLOGY, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.